Clinical bottom line
Circulating tumor DNA (ctDNA) kinetics during chemoradiation for head and neck cancer (HNC) represent a promising, yet still investigational, biomarker for real-time assessment of tumor response and prognosis. Early decreases in ctDNA levels, detected in plasma or saliva, may correlate with better treatment outcomes, while persistent or rising ctDNA could signal residual disease or treatment resistance. However, current evidence is limited to pilot and small cohort studies, and standardized protocols for ctDNA monitoring and interpretation are lacking. Incorporating ctDNA kinetics into adaptive treatment strategies could potentially personalize therapy intensity and improve outcomes, but this approach requires prospective validation.
What the evidence shows
Head and neck squamous cell carcinoma (HNSCC) is commonly treated with combined modality chemoradiation, which can be curative but carries significant toxicity (Eng et al., 2005). Monitoring treatment response traditionally relies on imaging and clinical examination, which may lag behind molecular changes. Circulating tumor DNA, shed by tumor cells into bodily fluids, offers a minimally invasive biomarker reflecting tumor burden and dynamics.
Several pilot studies have explored ctDNA detection in saliva and plasma of HNC patients undergoing chemoradiation. These studies demonstrate that ctDNA levels often decline during treatment, with early kinetics correlating with clinical response [1,3]. For example, rapid clearance of tumor-specific mutations in saliva ctDNA during the first weeks of chemoradiation has been associated with improved locoregional control and progression-free survival. Conversely, persistent ctDNA detection post-treatment may indicate minimal residual disease and higher relapse risk [2].
The dynamic changes in ctDNA levels during treatment provide a potential window for adaptive therapy. Patients with early ctDNA clearance might be candidates for de-escalation strategies to reduce toxicity, while those with persistent ctDNA could benefit from treatment intensification or early salvage interventions. However, these hypotheses remain untested in large, prospective clinical trials.
Caveats and uncertainty
The current evidence base is limited by small sample sizes, heterogeneous patient populations, and variability in ctDNA assay methods and sampling schedules. Most studies are pilot or feasibility reports without standardized thresholds for defining ctDNA positivity or kinetics. Saliva-based ctDNA assays, while noninvasive, may have lower sensitivity compared to plasma assays and are influenced by tumor location and oral hygiene [4].
Moreover, the biological interpretation of ctDNA kinetics during chemoradiation is complex. Tumor lysis and inflammation may transiently increase ctDNA levels, complicating early assessments. The optimal timing for ctDNA sampling to guide adaptive treatment remains unclear. Additionally, the impact of HPV status, tumor stage, and other clinical factors on ctDNA dynamics warrants further study.
Finally, no randomized trials have yet demonstrated that modifying treatment based on ctDNA kinetics improves patient outcomes. Thus, clinical implementation should be cautious and ideally confined to research settings.
How this may change practice
If validated, monitoring ctDNA kinetics during chemoradiation could become a valuable tool for personalized management of head and neck cancer. Integration of serial ctDNA measurements might enable oncologists to:
- Identify nonresponders early and escalate therapy or enroll patients in clinical trials.
- Select candidates for treatment de-escalation to minimize toxicity without compromising efficacy.
- Detect minimal residual disease post-treatment to guide surveillance intensity and adjuvant therapy decisions.
Incorporating ctDNA monitoring would require standardized, clinically validated assays and clear interpretation guidelines. Multidisciplinary collaboration and prospective trials are essential to establish clinical utility and cost-effectiveness.
Until such data are available, ctDNA kinetics should be considered an investigational biomarker and not yet used to alter standard chemoradiation protocols.